For an online-care question
State rules set the prescribing requirements and can differ, as of September 2026.
Use the board directory to find the regulator for your location.
The national group of state medical boards publishes guidance for boards.
It is useful for comparing care, but it is not a national law.
Open the guidance on care and the licence records
The medical boards’ guidance calls for follow-up questions rather than a treatment decision based solely on a patient’s menu choice.
For a medicine or pharmacy question
FDA is the Food and Drug Administration, the U.S. agency that regulates medicines.
When a doctor or pharmacist prepares a drug to order, that work is compounding.
Compounded drugs still lacked FDA approval in September 2026.
The agency does not check how well they work, how safe they are or how well they are made before sale.
Registration puts a medicine-making business in FDA’s records; listing puts a drug product in those records.
As of September 2026, FDA approval of a business or its medicine did not follow from either registration or listing.
Use the pharmacy licence record for the pharmacy. Use the product information for the medicine.
Open the pharmacy and compounding records
The shortage position can change; the September 2026 check found no national listing for semaglutide injection or tirzepatide.
For payment terms or help after care
September 2026 information describes the Medicare GLP-1 Bridge as temporary, with access to certain weight medicines for eligible people.
Some weight and diabetes medicines mimic GLP-1. This natural body signal influences blood sugar and appetite.
Read the programme’s own terms with the prescriber to check whether you fit them.
For a personal question about treatment, ask the clinician. For a label or shipment question, ask the pharmacy.
Open the public cost and help pages
MedWatch accepts reports about medicine problems from patients as well as health professionals.